Phaseline

Targets › MCIR

MCIR: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Immunology.

Open in Phaseline: the race on MCIR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Palatin TechnologiesPL8177
Melanocortin receptor agonist
MCIRPhase 2Ulcerative Colitis–

Conditions

Ulcerative Colitis (1)

Modalities

small molecule (1)

Companies

Palatin Technologies (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.